Optimizing antifungal dosing for invasive Cryptococcus infections: minimum inhibitory concentration distributions and pharmacokinetic/pharmacodynamic insights from 2010–2023 Antimicrobial Testing Leadership and Surveillance data
Diverging from the 2024 guidelines, this study provides novel insights into the treatment of <i>Cryptococcus</i> MME based on MIC distributions and PK-PD indices for antifungal agents.
Authors
- Chun-Chung Hsueh
- Po‐Ren Hsueh (ORCID: https://orcid.org/0000-0002-7502-9225)
- Shio-Shin Jean (ORCID: https://orcid.org/0000-0001-6431-7961)
- Chia‐Ying Liu (ORCID: https://orcid.org/0000-0002-8698-683X)
- Wei-Lun Chang
- Chih-Cheng Lai
- C. N. Weng
Institutions
- National Sun Yat-sen University (TW)
- China Medical University (TW)
- Min Sheng General Hospital (TW)
- Taipei Veterans General Hospital (TW)
- Tajen University (TW)
- Far Eastern Memorial Hospital (TW)
- China Medical University Hospital (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Lunghwa University of Science and Technology (TW)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-10
- DOI
- https://doi.org/10.3389/fphar.2025.1665253
- Primary Topic
- Fungal Infections and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00